Viewing Study NCT05270668

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:30 PM
Ignite Modification Date: 2026-01-24 @ 4:54 PM
Study NCT ID: NCT05270668
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-17
First Post: 2022-02-27
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Cutaneous Systemic Sclerosis View
None Interstitial Lung Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ATHENA SSc-ILD View
None ATHENA View
None Diffuse Cutaneous Scleroderma View
None Interstitial Lung Disease View